StockNews.AI
LEXX
StockNews.AI
75 days

Lexaria Attending BIO International Convention

1. Lexaria's CEO will attend BIO International Convention in June. 2. BIO is the largest biotech convention, promoting industry partnerships. 3. Lexaria seeks strategic partnerships for its DehydraTECH® drug candidates. 4. The company holds 48 patents and continues expanding its IP portfolio. 5. Lexaria emphasizes potential in clinical applications for weight loss and diabetes.

6m saved
Insight
Article

FAQ

Why Bullish?

Participation in a major event like BIO can enhance visibility and partnerships, historically boosting stock prices in biotech firms attending such conventions. Increased networking opportunities may lead to collaborations that could materially impact revenue and product development.

How important is it?

The article's focus on strategic partnerships and networking at a major convention directly aligns with LEXX's growth strategies, indicating potential bullish sentiment among investors.

Why Short Term?

The direct effects of meeting prospective partners at BIO are likely to show results in the near term as partnership announcements often follow such events, impacting LEXX's stock relatively quickly.

Related Companies

AMRNCRONGNPDTTNP
Biotechnology Sector's Premier Strategic Partnering Event Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ("BIO") in Boston, June 16-19.With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world. The convention provides a unique forum for networking and exploring collaborations. By participating in BIO 2025, Lexaria is seeking to advance discussions with prospective partners and strategic investors, to support the development of its clinical stage DehydraTECH® enhanced emerging drug product candidates.Lexaria is arranging a full slate of 1-on-1 meetings with global and regional corporate leaders in the fields of weight loss, diabetes and hypertension, among others. Lexaria has a limited number of meeting times still available. Interested parties are encouraged to reach out to the Company directly or via the BIO Partnering TM platform to request a meeting at BIO.About Lexaria Bioscience Corp. & DehydraTECHDehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.CAUTION REGARDING FORWARD-LOOKING STATEMENTSThis press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.INVESTOR CONTACT:George Jurcic - Head of Investor Relations[email protected]Phone: 250-765-6424, ext 202SOURCE: Lexaria Bioscience Corp.

Related News